TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022

Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score.

Barbara Burtness et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.